Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Impairment expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Zomedica

Zomedica Corp. operates as a veterinary health company, which engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. It offers products for dogs and cats by focusing on the unmet needs of clinical veterinarians. Its TRUFORMA biosensor platform is designed to assist practitioners in the diagnosis of complex conditions. The company was founded by Gerald L. Solensky. on January 7, 2013 and is headquartered in Ann Arbor, MI.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Zomedica reports revenue growth and product advancements amidst profitability challenges

Zomedica's 2022 performance reflects revenue growth and product advancements, though challenges in profitability persist. The company's strategic focus on companion animal healthcare presents growth opportunities through innovation and market stability. Addressing expense management, stock stability, and leveraging market trends will be key for Zomedica's future success.

Zomedica reports robust Q1 earnings, eyes global equine market

Zomedica's Q1 2023 showcased strong revenue growth, particularly driven by TRUFORMA and international sales.
The company's focus on maintaining margins, expanding marketing efforts, and targeting global equine markets positions it for future success.
Challenges include the closure of the cancer assay program and operational hurdles in achieving the 70% gross margin target.
Opportunities lie in the launch of new assays, international expansion, and investor engagement beyond quarterly updates.

Zomedica reports robust Q2 earnings, eyes international expansion and product launches

Zomedica's Q2 performance reflects strong revenue growth and strategic investments for future profitability.
Despite challenges like increased OpEx and lower margins, the company is focused on long-term growth through product launches and market expansion.
Opportunities lie in international market exploration, upcoming product launches, and investor engagement strategies.

Zomedica reports record revenues, eyes global expansion amidst stock challenges

Zomedica's Q3 performance reflects strong revenue growth and strategic acquisitions, despite facing challenges like potential delisting and net losses.
The company's focus on new product launches, international expansion, and partnerships presents opportunities for future growth and market diversification.
Overall, Zomedica aims to drive towards cash flow breakeven by leveraging innovative products and maintaining a strong liquidity position.

Zomedica reports record revenues, eyes profitability through strategic growth

Zomedica's strong financial performance in Q4 2023 and full-year results, coupled with a robust cash position and strategic growth initiatives, position the company for future success.
While facing challenges related to compliance requirements and integration costs, Zomedica's focus on innovation, market expansion, and profitability goals present opportunities for sustained growth.
By balancing operational efficiency, product development, and financial discipline, Zomedica aims to drive revenue growth, enhance market presence, and deliver long-term value to shareholders.

Zomedica reports revenue growth and strong cash position in Q1

Zomedica's Q1 2024 performance showed revenue growth driven by key segments, strong cash position, and focus on operational efficiency. The company faces challenges in managing expenses and achieving aggressive revenue targets. Opportunities lie in expanding product lines, international sales, and maintaining financial strength.

Zomedica reports Q2 revenue growth amidst challenges and opportunities

Zomedica's Q2 performance showed revenue growth but with challenges in sales force and noncash charges.
Strengths include achieving milestones and expanding facilities, while opportunities lie in international expansion.
The company faces the task of managing cash burn and finding a new CFO.
Expectations for the second half of 2024 include revenue growth and operational focus.

Zomedica reports record Q3 revenue, eyes global expansion opportunities

Zomedica's Q3 2024 performance showcased revenue growth, margin strength, and cost reduction efforts, positioning the company for future profitability. Strategic international partnerships and product innovations underscore growth potential.
While challenges in achieving profitability persist, Zomedica's focus on operational efficiency and global expansion presents opportunities for sustained growth. Addressing investor inquiries and executing on strategic initiatives will be key to unlocking future value.
With a solid cash position, ongoing product enhancements, and expansion into new markets, Zomedica is poised for growth. Clear communication on financial targets, operational milestones, and strategic direction will be crucial for investor confidence and market success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ANN ARBOR, MI / ACCESSWIRE / August 31, 2023 / Zomedica Corp. (NYSE American:ZOM), a veterinary health company offering point-of-care diagnostics and therapeutic products for companion animals, announced today that Larry Heaton, Chief Executive Officer, will provide a strategic update at the upcoming H.C. Wainwright 25th Annual Global Investment Conference, scheduled for 2:30 pm ET on September 13, 2023.

Zomedica to Present at H.C. Wainwright 24th Annual Global Investment Conference

Zomedica Corp. (NYSE:ZOM ) Q2 2023 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants Larry Heaton - Chief Executive Officer Peter Donato - Chief Financial Officer Operator Good afternoon, and welcome to Zomedica's Second Quarter 2023 Earnings Release Call. As a reminder, this call is being recorded and all participants are in listen-only mode.

Zomedica Corp. (ZOM) Q2 2023 Earnings Call Transcript

ANN ARBOR, MI / ACCESSWIRE / August 10, 2023 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for companion animals, today reported consolidated financial results for the quarter ended June 30, 2023. Amounts, unless specified otherwise, are expressed in U.S. dollars and presented under accounting principles generally accepted in the United States of America ("U.S. GAAP").

Zomedica Announces Record Second Quarter 2023 Financial Results: Revenue up 43% to $6.0 Million; Strong 67% Gross Margin & $142.4 Million in Liquidity

ANN ARBOR, MI / ACCESSWIRE / August 8, 2023 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for companion animals, announced Larry Heaton, CEO, will present and host one-on-one meetings with investors at the Sidoti August Virtual Investor Conference, taking place on August 16-17, 2023. The presentation will begin at 9:15 ET on Wednesday, August 16, 2023 and can be accessed live here: https://sidoti.zoom.us/webinar/register/WN_Mqr9yUzCQkW9cixbRcQLww Zomedica will also host virtual one-on-ones with investors on Wednesday and Thursday, August 16-17, 2023.

Zomedica to Present at Sidoti Virtual Investor Conference August 16-17

ANN ARBOR, MI / ACCESSWIRE / August 4, 2023 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering diagnostic and therapeutic products for companion animals, will host a conference call and audio-only webcast on Thursday, August 10, 2023 at 4:30 p.m. ET to discuss the Company's operational and financial highlights for its second quarter ending June 30, 2023.

Zomedica to Host Second Quarter Financial Results Call on August 10

Bullfrog AI Holdings Inc

Lantern Pharma

Reviva Pharmaceuticals

Sharps Technology Inc

New podcast series shines a spotlight on undervalued small-cap and microcap stocks ORLANDO, FL / ACCESSWIRE / August 2, 2023 / RedChip Companies, a renowned international investor relations firm specializing in microcap and small-cap companies,announce the launch of its much-anticipated podcast series, "Small Stocks, Big Money." Hosted by RedChip CEO Dave Gentry and Associate Director Barrett Boone, the "Small Stocks, Big Money" podcast aims to offer a first-hand look at undiscovered small-cap and microcap stocks before they catch the attention of bigger Wall Street players.

RedChip Launches 'Small Stocks, Big Money' Podcast

ANN ARBOR, MI / ACCESSWIRE / June 9, 2023 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a leading innovator in veterinary medicine offering diagnostic and therapeutic products for companion animals, announced today the launch of the revolutionary TRUVIEWTM digital microscopy platform, featuring the proprietary TRUprepTM system that automatically prepares slides, along with LiquiViewTM liquid lens technology that provides best-in-class images. Microscopic examination of blood and cytology fluids is the standard of care in the veterinary industry and is utilized by essentially every veterinary practice.

Zomedica Launches Revolutionary TRUVIEW(TM) Digital Microscope with Advanced Optics, Automated Slide Preparation, and Telepathology Services

ANN ARBOR, Ml / ACCESSWIRE / May 12, 2023 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering diagnostic and therapeutic products for companion animals, announced today that Larry Heaton, Chief Executive Officer, will be participating in a Company Webcast and Panel Presentation at the Lytham Partners Spring 2023 Investor Conference on Thursday, May 18, 2023. Management will also be conducting one-on-one meetings with investors.

Zomedica to Participate in the Lytham Partners Spring 2023 Investor Conference

B2Gold

Denison Mines

RLX Technology

Superior Drilling Products

Super Group SGHC Ltd

VTEX

Before diving into the discussion about the most promising penny stocks to buy in May, a caveat is in order: when you enter this arena, you must be prepared to lose money. Sure, it's always possible to make serious dough.

The 7 Most Promising Penny Stocks to Buy in May 2023

Zomedica Corp. (NYSE:ZOM ) Q1 2023 Results Conference Call May 11, 2023 4:30 PM ET Company Participants Larry Heaton - CEO Peter Donato - CFO Conference Call Participants Jason Kolbert - Dawson James Operator Good afternoon, ladies and gentlemen and welcome to Zomedica's First Quarter of 2023 Earnings Release Call. As a reminder, this call is being recorded and all participants are in a listen-only mode.

Zomedica Corp. (ZOM) Q1 2023 Earnings Call Transcript

ANN ARBOR, MI / ACCESSWIRE / May 11, 2023 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for companion animals, today reported consolidated financial results for the three months ended March 31, 2023. Amounts, unless specified otherwise, are expressed in U.S. dollars and presented under accounting principles generally accepted in the United States of America ("U.S. GAAP").

Zomedica Announces Record First Quarter 2023 Financial Results: Revenue up 45% to $5.5 Million; Strong 70% Gross Margin & $147.5 Million in Liquidity

ANN ARBOR, Ml / ACCESSWIRE / May 8, 2023 / Zomedica Corp. (NYSE American:ZOM) ('Zomedica' or the 'Company'), today announced it has exercised its option to move forward with the acquisition of Structured Monitoring Products, Inc. (SMP), the makers of VetGuardian™ zero-touch vital signs remote monitoring system, at a previously negotiated purchase price. Exercising this option began a period where the companies have agreed to work together to complete due diligence and negotiate a definitive acquisition agreement.

Zomedica Exercises Option to Acquire Structured Monitoring Products

ANN ARBOR, MI / ACCESSWIRE / May 2, 2023 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering diagnostic and therapeutic products for companion animals, will host a conference call and audio-only webcast on Thursday, May 11, at 4:30 p.m. ET to discuss the Company's operational and financial highlights for its first quarter ending March 31, 2023.

Zomedica to Host First Quarter Financial Results Call on May 11

MaxCyte

ProPhase Labs

CorMedix

Matinas BioPharma Hlds

Ocuphire Pharma

Sensus Healthcare

While unproven biotechnology firms almost always carry significant risks, small-cap biotech stocks in particular typically impose jaw-dropping volatility. Along with the usual risk of clinical disappointments or outright failures, these speculative enterprises are obviously less funded.

7 Small-Cap Biotech Stocks with Massive Potential

Cipher Mining

Immutep Ltd

Newegg Commerce

Valens Semiconductor Ltd

There are speculative ideas and then there are the best penny stocks under $3. And don't be fooled by the word “best.

7 Best Penny Stocks Under $3 to Buy in April

ORLANDO, FL / ACCESSWIRE / March 31, 2023 / RedChip Companies will air a new interview with Zomedica Corp. (NYSE American:ZOM) on The RedChip Money Report® on Bloomberg TV, this Saturday, April 1, at 7 p.m. Eastern Time (ET).

Zomedica Corp. Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)

Zomedica had huge gains in revenue in 2022. The company specializes in products for clinical veterinarians.

Why Shares of Zomedica Were Zooming Monday

ANN ARBOR, MI / ACCESSWIRE / March 17, 2023 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for companion animals, announced that it has appointed Peter L. Donato as its Chief Financial Officer, effective March 16, 2023.

Zomedica Appoints New Chief Financial Officer

Zomedica Corp. (NYSE:ZOM ) Q4 2022 Earnings Conference Call March 15, 2023 4:30 PM ET Company Participants Larry Heaton - Chief Executive Officer Ann Cotter - Chief Financial Officer Paul Kuntz - Investor Relations Greg Blair - Vice President, Business Development & Strategic Planning Conference Call Participants Operator Good afternoon, and welcome to Zomedica's Fiscal Year 2022 Earnings Release Call. As a reminder, this call is being recorded and all participants are in a listen-only mode.

Zomedica Corp. (ZOM) Q4 2022 Earnings Call Transcript

ANN ARBOR, MI / ACCESSWIRE / March 15, 2023 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for companion animals, today reported consolidated financial results for the year ended December 31, 2022. Amounts, unless specified otherwise, are expressed in U.S. dollars and presented under accounting principles generally accepted in the United States of America ("U.S. GAAP").

Zomedica Corporation Reports 2022 Results: $18.9 Million Revenue; 72% Gross Margin & $156 Million in Liquidity - Revenue up 361% from 2021 through combination of acquisitions and organic growth

ANN ARBOR, MI / ACCESSWIRE / March 8, 2023 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering diagnostic and therapeutic products for companion animals, will host a conference call and audio-only webcast on Wednesday, March 15, at 4:30 p.m. ET to discuss the Company's operational and financial highlights for its fourth quarter and fiscal year ended December 31, 2022.

Zomedica to Host Fourth Quarter and Fiscal Year 2022 Financial Results Call on March 15

ANN ARBOR, MI / ACCESSWIRE / February 9, 2023 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for companion animals, today reported its preliminary unaudited results for the fourth quarter and year ended 2022. Preliminary (unaudited) Fourth Quarter and Full Year 2022 Results: Revenue for the fourth quarter of 2022 is expected to be approximately $6.0-$6.2 million, an increase of 46-51% compared to the same prior year period, primarily driven by an increase in PulseVet® sales and the inclusion of the recently acquired Assisi® products.

Zomedica Reports Preliminary Results for the Fourth Quarter and Full Year 2022

ORLANDO, FL / ACCESSWIRE / February 8, 2023 / RedChip Companies will air a new interview with Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or "Company") on The RedChip Money Report® on Bloomberg TV, this Saturday, February 11, at 7 p.m. Eastern Time (ET).

Zomedica Interview To Air on Bloomberg U.S. on the RedChip Money Report(R)

ANN ARBOR, MI / ACCESSWIRE / January 24, 2023 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or "Company") announced today that the Company will be participating in the Lytham Partners Investor Select Conference taking place virtually on January 31, 2023. Company Webcast The Company's webcast presentation will be available for viewing at 9:00am ET on Tuesday, January 31, 2023, at https://wsw.com/webcast/lytham7/zom/1898244, and subsequently on the Company's website at www.ZOMEDICA.com.

Zomedica to Participate in the Lytham Partners Investor Select Conference

Zomedica (NYSEMKT: ZOM ) stock is on the rise Wednesday after the company signed a strategic restructuring agreement with Qorvo Biotechnologies. This has to do with the licensing agreement concerning the TRUFORMA line of products.

News for Zomedica Stock (ZOM)